Skip to main content
TipRanks
Go Ultimate75% OFF

Bioqual (BIOQ) AI Stock Analysis

19 Followers
BIOQ

Bioqual

(Other OTC:BIOQ)

Select Model
Rating:38Underperform
Price Target:$31.00â–²(2.48% Upside)
Action:downgraded
Date:10/24/26

The overall score is deeply bearish, driven primarily by a severe and accelerating deterioration in financial performance. The company has shifted from profitability to significant losses, taken on an unsustainable debt load, and is now burning cash. This fundamental weakness is confirmed by a bearish technical trend, with the stock trading below all major moving averages. The negative P/E ratio further underscores the lack of earnings power. The combination of a collapsing business model and high leverage presents a critical risk profile.

Positive Factors
Revenue ReboundThe sharp TTM revenue rebound indicates renewed demand for BIOQ’s services and provides a larger base from which operating performance can recover. If sustained, stronger sales should improve utilization, support investment in capabilities, and reinforce customer relationships over the coming quarters.
Negative Factors
Persistent LossesThe return to sizable losses shows that current revenue levels are not producing adequate earnings after costs. Continued negative margins can erode equity, restrict reinvestment, and make future performance dependent on a successful improvement in pricing, mix, or operating efficiency.

Bioqual (BIOQ) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%BIOQ-21.45%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$27.73M
Dividend Yield
―
Average Volume (3M)
557
Price to Earnings (P/E)
-6.3
Beta (1Y)
-0.19
Revenue Growth
-14.30%
EPS Growth
-610.16%
Country
US
Employees
278
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Bioqual Business Overview & Revenue Model

Company Description

Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise spans numerou...

Bioqual Financial Statement Overview

Summary

Financial performance is critically weak. Revenue has declined nearly 40% from FY2022 to TTM, gross margin has collapsed to 3.6%, and the company is generating significant net losses (-$4.4M TTM). The balance sheet shows a dangerous surge in debt-to-equity to 1.01, and operating cash flow has turned negative. The overall trend indicates a fundamental breakdown in the business model and a potential solvency crisis.

Income Statement

8Very Negative

Balance Sheet

18Very Negative

Cash Flow

5Very Negative
Financial statement breakdown
BreakdownTTMAug 2025Aug 2024Aug 2023May 2023Aug 2021
Income Statement
Total Revenue40.24M39.95M48.87M58.59M62.66M66.15M
Gross Profit1.05M1.43M-1.90M7.43M12.60M13.01M
EBITDA-1.56M-2.25M473.97K3.03M6.97M14.76M
Net Income-4.41M-4.17M-1.05M483.48K835.55K5.26M
Balance Sheet
Total Assets67.41M68.44M57.12M56.59M61.32M63.34M
Cash, Cash Equivalents and Short-Term Investments16.47M16.01M17.85M15.59M7.28M2.18M
Total Debt31.92M32.71M16.54M3.59M18.61M18.72M
Total Liabilities35.46M36.04M20.96M18.94M23.70M25.67M
Stockholders Equity31.95M32.41M36.15M37.65M37.61M37.67M
Cash Flow
Free Cash Flow-650.68K-66.78K2.71M8.76M5.99M-4.57M
Operating Cash Flow-165.45K351.44K2.94M9.36M8.23M313.36K
Investing Cash Flow-7.46M-7.08M-238.78K-597.13K-2.24M-4.73M
Financing Cash Flow00-447.21K-447.21K-894.42K-1.12M

Bioqual Technical Analysis

Technical Analysis SentimentNegative
Last Price30.25

Price Trends

50DMA32.55Negative
100DMA33.15Negative
200DMA34.50Negative

Market Momentum

MACD-0.74Negative
RSI24.49Positive
STOCH50.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOQ, the sentiment is Negative. The current price of 30.25 is below the 20-day moving average (MA) of 30.76, below the 50-day MA of 32.55, and below the 200-day MA of 34.50, indicating a bearish trend. The MACD of -0.74 indicates Negative momentum. The RSI at 24.49 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOQ.

Bioqual Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BIOQ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PRPOPRPO65Neutral$34.37M-31.63-7.84%―21.76%22.97%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BDSXBDSX44Neutral$98.47M-3.24-442.34%―31.23%48.56%
VNRXVNRX44Neutral$6.81M-0.0677.30%―134.01%32.90%
BNGOBNGO42Neutral$13.31M-0.36-85.00%―8.23%82.76%
BIOQBIOQ38Underperform$27.04M-6.29-13.07%―-14.30%-610.16%

* Healthcare Sector Average

Performance Comparison

-100%0%100%200%300%BIOQVNRXPRPOBNGOBDSXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BIOQ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BIOQBioqual 30.25-8.26-21.45%
VNRXVolitionRX Ltd.0.19-6.37-97.13%
PRPOPrecipio19.17-7.08-26.97%
BNGOBionano Genomics0.95-0.59-38.18%
BDSXBiodesix, Inc.8.881.9828.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 24, 2026